Project Grant R01HL174373
Award Date
9/15/24
Completion Date
6/30/28
Dollars Obligated
$712K
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60637, USA
Similar Awards
This federal Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $671,732 to The Washington University to conduct research on the mechanisms underlying fentanyl-induced cardiorespiratory depression. The goal is to evaluate the use of peripherally-acting mu opioid receptor (MOR) antagonists to prevent and reverse fentanyl overdoses without the aversive withdrawal effects seen with naloxone. The research also aims...
This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $640,000 to Olfa Thera, Inc. to develop new therapeutics targeting the OLFR78/OR51E2 receptor pathway in the carotid body. The goal is to identify OLFR78/OR51E2 agonists that can strongly stimulate carotid body activity and ventilation to reverse opioid-induced respiratory depression, without the side effects of existing...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $249,000 to Dr. Nicholas Burgraff at the University of Wisconsin - Madison. The funding will support Dr. Burgraff's research to unravel the mechanisms of opioid-induced airway constriction, with the goal of developing novel therapeutics for opioid overdose. The research aims to expand understanding of the neural circuits and autonomic...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,536 to Chemregen Inc.'s Human Biomolecular Research Institute in San Diego, CA. The funding supports research to design, synthesize, and test non-opioid drug candidates as potential treatments for opioid use disorder and fentanyl toxicity. Key objectives include characterizing the effects of opioids on human induced pluripotent stem...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a research study focused on understanding the impact of the opioid fentanyl on individuals with HIV. The total funding amount is $587,188, with the award period running from July 15, 2025 to March 31, 2030. The key products and services to be delivered under this grant include: A multi-omics approach and complementary in vivo and ex vivo studies to...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $267,310 to the University of Miami to assess the functional role of calcitonin gene-related peptide (CGRP) expressing neurons within the parabrachial nucleus (CGRPPBN) in opioid reinforcement and to determine the associated gene expression and epigenetic changes. The goal is to explore non-opioid targets to treat opioid use disorder, a...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $475,500 to Indiana University to conduct research on using negative allosteric modulators (NAMs) of the mu opioid receptor (MOR) to reverse fentanyl overdose. The key objectives are to: 1) Screen a library of cannabidiol (CBD) analogs to identify potent NAMs that can attenuate fentanyl's signaling through MOR across multiple pathways, beyond...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,333,597.00 to Yale University to conduct research on brain kappa opioid receptors in individuals with opioid use disorder (OUD). The key objectives are to: 1) Use PET imaging to compare kappa opioid receptor availability in early abstinent OUD patients versus healthy controls; 2) Explore the links between kappa opioid receptor...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research on the impact of fentanyl consumption on noradrenergic plasticity in the basolateral amygdala. The $184,706 award to the University of North Carolina at Chapel Hill will fund a 5-year study to investigate how patterns of fentanyl consumption and withdrawal alter brainstem noradrenergic neurons and disrupt norepinephrine signaling in the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the CFDA program "Drug Use and Addiction Research Programs" (93.279), will support research to uncover the neurophysiological signatures within the addiction circuitry related to acute opioid use. The $159,711 award, effective January 1, 2025 through December 31, 2029, will leverage a unique ability to directly record local field potentials from awake humans with implanted brain electrodes. This will...